Become A Featured Company

CFN Media Interviews Organigram

Ryan Allway

December 13th, 2017

News, Top News

The legal cannabis market in Canada is exploding and with full legalization only months away, and it will only be a matter of time before the country is bringing in billions of dollars in revenue. The country’s licensed producers are responsible for providing safe and effective medicine to registered patients. Organigram (CVE: OGI)(OTCQB:OGRMF) was among the first LPs in Canada and have set the standard in terms of both cultivation and strain development. The company recently announced the launch of The Edison Project by OGI, an initiative that combines cutting-edge technology and advanced research and development to create the highest-quality flower on the market.

CFN Media recently spoke with Organigram Chief Commercial Officer Ray Gracewood at the annual Marijuana Business Conference in Las Vegas about the company’s recent developments and their plans to gain market share in Canada and beyond.

CFN:  What is the history of Organigram as a licensed producer of cannabis?

Ray Gracewood: Organigram has been in business since 2013, granted by Health Canada. We operate out of Moncton, New Brunswick, and we’re currently in the middle of a significant expansion that takes us from 32,000 square feet to 177,000 square feet of production space, resulting in annualized production of 25,000kg. The most recent phase of that is scheduled for completion at the end of this calendar year, so we’ll have plants in the facility by the end of January. That will position us very well for the emerging adult-use market starting in July. Further, we’ve recently announced funding that will allow us to start construction on a further expansion, bringing our entire footprint to 429,000 square feet of production space over 17.5 acres. This project will increase our overall capacity to 65,000kg per year.

CFN:  What distinguishes you from other LPs and how do end users benefit from your products?

RG:  There are several things from a medical perspective that position us a little bit differently. It starts with our focus on client service. Being a company from New Brunswick, Canada, we’re completely bilingual, but we’ve also had a very patient-focused, compassionate view on what it means to be a patients’ licensed producer of medical cannabis.  We realize how important it is to help them not only feel comfortable going through the process, but also understanding that we’re there for them as a company. I believe we deliver that one-to-one service better than anybody else in this space.

We’ve also spent the past year focusing on product quality, and understanding what it means to be a world class producer of indoor-grown cannabis. We firmly believe that indoor grown product demands a premium and if done correctly, will result in the best product in the market.  We are also very focused on understanding diversity of products, so that our patients have a good selection to choose from, whether that’s a dried flower, or cannabis oil, or different forms as they evolve and then become allowed through the regulatory system.  Most recently we’ve launched the Edison Project, our top-quality product showcasing the potential of the cannabis plant. We’ve spent over two years perfecting our growing and curing process, resulting in an incredibly premium, hand-manicured line of cannabis strains.

CFN:  Why should potential investors consider buying stock in Organigram?

RG:  From our perspective, it starts with the business opportunity that our location provides us.  There are two major drivers of cost in our industry from a production perspective – power and labour.  As a New Brunswick-based company, we enjoy some of the lowest rates in both areas, allowing us to focus our efforts on innovation and improving product quality.

Secondly, I believe in our focus on building our business strategically with an industry-leading management team. Whether it’s consumer-packaged goods, running major production facilities, or prior industry experience at the senior level, our leadership team has the experience to take Organigram confidently into the future. The cannabis industry affords such incredible opportunities, but only the strongest and most experienced teams will be able to adapt and scale up.

Lastly and most importantly, with one of the largest indoor facilities in the country how we operate allows us to align with our focus and commitment on quality in the products we produce, and the services we provide,

CFN:  What are your projections for growth as the cannabis market in Canada continues to explode?

RG: Currently, we have a capacity of about 5,200 kilograms. Through the next phase of expansion, we will have the capability to produce 25,000 kilograms on an annualized basis in 2018. With the most recent expansion announcement, it positions us as a leading indoor grower in Canada, extending our capacity by another 40,000 kilograms/year to approximately 65,000 kg/year.

Every week there seems to be another announcement of Provinces a establishing their distribution and retail plans. We’re looking at every market in Canada through this process to understand how each provincial framework fits into our business strategy within the adult recreational marketplace.  Our intention is to build business from coast to coast, but we also need to ensure priorities are put in place to fulfill our business objectives. As we’ve communicated in the past, medical patients will continue to be our top priority and we’ll ensure medicine is available to all registered patients as we get closer to next July.

We have no concerns in finding medical patients and adult recreational consumers for all this product domestically, although we are also exploring options internationally.  We recently appointed a new VP of International Business, which will be firmly focused on the significant interest we’ve had in Organigram from potential partners outside of Canada. The process to determine what opportunities need to be explored, in what countries, and with what partners is something we’re focusing on through the balance of this year and into 2018 and beyond.

CFN: What else should investors – and the cannabis industry as a whole – know about Organigram?

RG:  It’s worth noting that we’ve been a very successful company within the medical space, but we see massive opportunities in the adult recreational space. One of the key things that we’re focusing on, aside from operational excellence and product quality is understanding that we need to come to market with a portfolio of brands that will accommodate different consumer types.

We’ve come an incredibly long way as an industry leading indoor grower, and we feel like we have the brand strategy to effectively target a diverse group of consumers within the adult recreational marketplace as of next year. We feel that the market will eventually be all about segmentation, and understanding how different products play a role at different times in people’s lives. The way consumers relate to those brands is going to really define the difference between a success and failure. Therefore, we’re doing a lot of that thought leadership and strategy work right now to position ourselves, not just for success in 2018, but also to set ourselves up for success in 2028, 2038 and beyond.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading